

Docket No. 50682000100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 5, 2002.

LILIA OLSEN

#7
B
5-16-02
RECEIVED
FEB 10 2002
PATENT & TRADEMARK OFFICE
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

J. Wohlgemuth et al.

Serial No.: 10/006,290

Filing Date: October 22, 2001

For: LEUKOCYTE EXPRESSION
PROFILING

Examiner: To Be Assigned

Group Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ **Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.**
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 506612000100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: February 5, 2002

Respectfully submitted,

By: Michael R. Ward

Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522



PTO/SB/08 (2-92)

Sheet 1 of 2

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 506612000100

Application Number 10/006,290

Applicant

Filing Date October 22, 2001

Mailing Date February 5, 2002

Wohlgemuth et al.
App Art Unit 1645
TECH CENTER 1600/2900FEB 20 2002
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	11/09/1982	4,358,535	Falkow et al.			
	2.	08/09/1988	4,762,780	Spector et al.			
	3.	05/07/1996	5,514,556	Shearer et al.			
	4.	10/29/1996	5,569,583	Greenberg et al.			
	5.	06/03/1997	5,635,365	Ansari et al.			
	6.	08/19/1997	5,658,744	Ochoa et al.			
	7.	08/17/1999	5,939,270	Haunsø et al.			
	8.	10/12/1999	5,965,366	Ochoa et al.			
	9.	11/21/2000	6,150,121	Hamawy et al.			
	10.	05/01/2001	6,225,084 B1	Falb et al.			
	11.	10/16/2001	6,303,321 B1	Tracey et al.			
	12.	10/23/2001	6,306,602 B1	Sillekens et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	13.	12/07/2000	WO 00/73498 A1	WIPO			
	14.	12/28/2000	WO 00/78808 A1	WIPO			
	15.	11/01/2001	WO 01/81916 A2	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	16.	Abdallah, A. N. et al. (1997) "Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy" <i>European Heart Journal</i> 18: 1024-1029.
	17.	Akalin, Enver et al. (2001) "Gene Expression Analysis in Human Renal Allograft Biopsy Samples Using High-Density Oligoarray Technology" <i>Transplantation</i> 72 (5): 948-953.

EXAMINER: (examiner)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 506612000100

Application Number 10/066,290


Applicant

J. Wohlgenuth et al.

Filing Date October 22, 2001

Patent Art Unit 1645

Mailing Date February 5, 2002




- | | |
|-----|---|
| 18. | Alpert, Susan et al. (1995) "The Relationship of Granzyme A and Perforin Expression to Cardiac Allograft Rejection and Dysfunction" <i>Transplantation</i> 60 (12): 1478-1485. |
| 19. | Chang, D. M. et al. (1996) "Cytokines and Cell Surface Markers in Prediction of Cardiac Allograft Rejection" <i>Immunological Investigations</i> 25 (1&2): 13-21. |
| 20. | Deng, Mario C. et al. (1995) "The Relation of Interleukin-6, Tumor Necrosis factor- α , IL-2, and IL-2 Receptor Levels to Cellular Rejection, Allograft Dysfunction, and Clinical Events Early After Cardiac Transplantation" <i>Transplantation</i> 60 (10): 1118-1124. |
| 21. | Grant, Simon C. D. et al. (1996) "Serum Cytokines in Human Heart Transplant Recipients" <i>Transplantation</i> 62 (4): 480-491. |
| 22. | Kimball, P. et al. (1995) "Cytokine Panel Predicts Early Rejection of Therapeutic Response After Cardiac Transplantation" <i>Transplantation Proceedings</i> 27 (1): 1286-1287. |
| 23. | Legros-Maida, Sabine et al. (1994) "Granzyme B and perforin can be used as predictive markers of acute rejection in heart transplantation" <i>Eur. J. Immunol.</i> 24: 229-233. |
| 24. | Marcelin, Anne-Genevieve et al. (2001) "Effects of Cyclosporine and Hydrocortisone on Kaposi's Sarcoma-Associated Herpesvirus Genome Replication and Cell Apoptosis Induction" <i>Transplantation</i> 72 (10): 1700-1708. |
| 25. | Saiura, Akio et al. (2001) "A Comparison of Gene Expression in Murine Cardiac Allografts and Isografts by Means DNA Microarray Analysis" <i>Transplantation</i> 72 (2): 320-329. |
| 26. | Schena, Mark et al. (1995) "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray" <i>Science</i> 270: 467-470. |
| 27. | Schena, Mark et al. (1996) "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>Proc. Natl. Acad. Sci. USA</i> 93: 10614-10619. |
| 28. | Sharma, Vijay K. et al. (1996) "Molecular Executors of Cell Death- Differential Intrarenal Expression of Fas Ligand, Fas, Granzyme B, and Perforin During Acute and/or Chronic Rejection of Human Renal Allografts" <i>Transplantation</i> 62 (12): 1860-1866. |
| 29. | Strehlau, Jurgen et al. (1997) "Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation" <i>Proc. Natl. Acad. Sci. USA</i> 94: 695-700. |
| 30. | Xia, Dongyuan et al. (2001) "Real-Time Polymerase Chain Reaction Analysis Reveals an Evolution of Cytokine mRNA Production in Allograft Acceptor Mice" <i>Transplantation</i> 72 (5): 907-914. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



1645

TECH CENTER 1600/2900
FEB 9 2002

RECEIVED

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 051-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/006,290	
	Filing Date	October 22, 2001	
	First Named Inventor	Jay WOHLGEMUTH, et al.	
	Group Art Unit	1645 ✓	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	11	Attorney Docket No.	506612000100

RECEIVED
APR 2 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): RETURN RECEIPT POSTCARD
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Request for Refund		
SUPPLEMENTAL Information Disclosure Statement - 3 pgs IN DUPL <input checked="" type="checkbox"/> PTO-1449 - 2 pgs IN DUPL with [30] references attached <input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Morrison & Foerster LLP 425 Market Street, San Francisco, CA 94105-2842 Michael R. Ward (Reg. No. 38,651)
Signature	<i>Michael R. Ward</i>
Date	February 5, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on February 5, 2002.	
<i>[Signature]</i> LILIA OLSEN	